Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2026 ,inter alia, to consider and approve the proposal for ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sudarshan Pharma Industries Ltd has scheduled a Board meeting on May 15, 2026 to consider and approve the issuance of Foreign Currency Convertible Bonds (FCCBs). The proposal requires receipt of applicable regulatory and statutory approvals. This decision follows prior shareholder approval obtained on August 11, 2025, and in-principle approval received from BSE Limited on September 26, 2025. The company filed this intimation under SEBI Listing Regulations. FCCBs are debt instruments that can be converted into equity shares at a predetermined conversion price.
This FCCB issuance could raise foreign capital for the company but may dilute existing shareholder equity if bondholders convert to shares. The actual impact depends on the size of issuance and conversion terms to be finalized.